Matches in Wikidata for { <http://www.wikidata.org/entity/Q81742060> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q81742060 description "article scientifique publié en 2005" @default.
- Q81742060 description "artículu científicu espublizáu en xunu de 2005" @default.
- Q81742060 description "scientific article published on 01 June 2005" @default.
- Q81742060 description "wetenschappelijk artikel" @default.
- Q81742060 description "наукова стаття, опублікована в червні 2005" @default.
- Q81742060 name "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based" @default.
- Q81742060 name "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based" @default.
- Q81742060 type Item @default.
- Q81742060 label "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based" @default.
- Q81742060 label "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based" @default.
- Q81742060 prefLabel "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based" @default.
- Q81742060 prefLabel "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based" @default.
- Q81742060 P1433 Q81742060-EE62C4F4-D029-4BB8-92F4-7B055C4972D4 @default.
- Q81742060 P1476 Q81742060-18F4E8A0-07D2-407F-B2C4-87ADF1BD77CF @default.
- Q81742060 P2093 Q81742060-114A630C-EAF5-4B6D-A393-A07C1B10555B @default.
- Q81742060 P2093 Q81742060-34491576-F735-4035-AA56-AB5638BE4087 @default.
- Q81742060 P2093 Q81742060-5237E33F-C59F-4067-8BFD-41D4BA567029 @default.
- Q81742060 P2093 Q81742060-65B88272-8300-4F70-883F-C30A263EE106 @default.
- Q81742060 P2093 Q81742060-7BDECBFC-139D-48A8-B384-672BBFCFC563 @default.
- Q81742060 P2093 Q81742060-877F3205-841F-4BFA-A55E-8F7B779EE271 @default.
- Q81742060 P2093 Q81742060-9DB27723-CAF9-4568-A5B9-D3BDB7A19F1B @default.
- Q81742060 P2093 Q81742060-A95E4D95-61F9-42DC-BC30-D467E41B9867 @default.
- Q81742060 P2093 Q81742060-B0D4A293-7963-472D-BF66-982EBB91979D @default.
- Q81742060 P2093 Q81742060-E996EF6F-FD5A-4387-AB19-45F0A94B5CBA @default.
- Q81742060 P2093 Q81742060-ED548B6B-559B-4B3A-85E7-6974103C4C82 @default.
- Q81742060 P2093 Q81742060-EDEE0A05-31CD-45B4-832F-8A364403E546 @default.
- Q81742060 P2093 Q81742060-F27E1D32-D8AF-4D14-B466-F7B5505B4D58 @default.
- Q81742060 P304 Q81742060-FADF4441-4766-4D11-B003-FF681FA49FC3 @default.
- Q81742060 P31 Q81742060-D19A0EAF-FF78-4B04-A87D-227691FCD6C9 @default.
- Q81742060 P356 Q81742060-A7B40A9D-7F2A-4516-A305-7689F05418C5 @default.
- Q81742060 P407 Q81742060-188D4A3C-00DE-4238-ABD8-36A1B90E227D @default.
- Q81742060 P433 Q81742060-33E95268-1FD5-4191-9003-A9C4C2421014 @default.
- Q81742060 P478 Q81742060-558F576A-79F4-44D2-8D84-274AC9055C7F @default.
- Q81742060 P577 Q81742060-0F668FF2-D484-49A9-AEAF-38B81591EE6A @default.
- Q81742060 P698 Q81742060-C8F0526C-2794-4924-A081-25AAEA2D4039 @default.
- Q81742060 P356 J.IJROBP.2004.09.047 @default.
- Q81742060 P698 15890569 @default.
- Q81742060 P1433 Q2296252 @default.
- Q81742060 P1476 "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group" @default.
- Q81742060 P2093 "Alan Pollack" @default.
- Q81742060 P2093 "Arnab Chakravarti" @default.
- Q81742060 P2093 "Chin-Lee Wu" @default.
- Q81742060 P2093 "David Grignon" @default.
- Q81742060 P2093 "Donald Kaufman" @default.
- Q81742060 P2093 "Elizabeth Hammond" @default.
- Q81742060 P2093 "Howard Sandler" @default.
- Q81742060 P2093 "Kathryn Winter" @default.
- Q81742060 P2093 "Matthew Parliament" @default.
- Q81742060 P2093 "Michael Hagan" @default.
- Q81742060 P2093 "Niall Heney" @default.
- Q81742060 P2093 "William Shipley" @default.
- Q81742060 P2093 "William Tester" @default.
- Q81742060 P304 "309-317" @default.
- Q81742060 P31 Q13442814 @default.
- Q81742060 P356 "10.1016/J.IJROBP.2004.09.047" @default.
- Q81742060 P407 Q1860 @default.
- Q81742060 P433 "2" @default.
- Q81742060 P478 "62" @default.
- Q81742060 P577 "2005-06-01T00:00:00Z" @default.
- Q81742060 P698 "15890569" @default.